arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BOSTON SCIENTIFIC CORP

BSX
$49.32 ▲ +0.05 (+0.09%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
74 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
76
Health
Good
Neutral
auto_awesome

Analytical Summary

BOSTON SCIENTIFIC CORP shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $73.2B
Dividend Yield
Revenue Growth 11.6%
Op. Margin 21.2%
ROIC 4.9%
FCF / Share $0.12
Trailing P/E 54.8x
Price / Book 2.8x
FCF Yield 0.2%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.20B
↑ +11.6%
Net Income Profit after all expenses
$1.34B
↑ +99.3%
Operating Margin Operating profit as % of sales
21.2%
↑ +35.6% 72th
FCF / Share Free cash flow per share
$0.12
↓ -51.9%
Long-Term Debt Long-term obligations
$4.81B
— +0.1%

Health Breakdown

Profitability
75
Returns
73
Financial Health
83
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters